Indication

As monotherapy for the treatment of adults with advanced rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

Medicine details

Medicine name:
selpercatinib (Retsevmo)
SMC ID:
SMC2371
Pharmaceutical company
Eli Lilly and Company Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Publication due date:
08 November 2021
SMC meeting date:
05 October 2021
Patient group submission deadline:
05 July 2021